1 Min Read
Dec 5 (Reuters) - Novartis Ag:
* NOVARTIS PHARMACEUTICALS CANADA - RYDAPT (MIDOSTAURIN) HAS BEEN APPROVED FOLLOWING A PRIORITY REVIEW BY HEALTH CANADA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.